VRAY - VRAY STOCK NEWS

ViewRay, Inc. (Nasdaq: VRAY) has received a letter from Nasdaq stating that its securities will be delisted due to the company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code and concerns about its ability to meet the minimum bid price requirement. Trading of the company's stock will be suspended on July 26, 2023, and it is expected to begin trading on the OTC markets under the symbol 'VRAYQ'. The transition to the OTC markets will not affect the company's operations in chapter 11.

ViewRay, Inc. has filed for Chapter 11 bankruptcy and plans to sell its business. The company has secured $6 million in debtor-in-possession financing to support ongoing operations. The CEO and two board members have resigned, and new appointments have been made.

ViewRay, Inc. announced that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center. This will be the first cancer center in Oklahoma and the fourth VA medical center offering Veterans access to MRIdian's advanced MRI-guided radiation therapy to treat cancer.

ViewRay, Inc. (NASDAQ: VRAY) announces details for the release of Q1 2023 financial results and conference call.

ViewRay, Inc. announces preliminary financial results for Q1 2023. Received 13 new orders for MRIdian systems totaling $68 million. Total backlog increased to $411 million. Total revenue for Q1 2023 was $23 million. Net loss for Q1 2023 was $29 million. Adjusted EBITDA was a loss of $25 million. Company's Board of Directors retained Goldman Sachs as financial advisor to evaluate strategic alternatives.

ViewRay, Inc. (NASDAQ: VRAY) has scheduled a conference call for April 13, 2023, at 8:00 AM ET to discuss preliminary financial results for the first quarter of 2023. Domestic callers can join at (888) 886-7786 using confirmation number 56031524. A live webcast will also be available on ViewRay's investor relations page. The MRIdian® MR-Guided Radiation Therapy System, designed with high-definition MR imaging, addresses challenges in advanced radiation oncology, such as beam distortion and skin toxicity. This innovative technology differentiates itself from conventional MR systems used in diagnostic radiology.

ViewRay (NASDAQ: VRAY) announced that the Czech Ministry of Health has approved the acquisition of its MRIdian system, making it the first and only facility to provide advanced MRI-guided radiation therapy in the Czech Republic at the Military University Hospital Prague. This purchase, partially funded by the REACT-EU financial instrument, enhances cancer treatment options with precision technology that includes real-time tissue tracking and automatic beam control. Over 29,000 patients have already benefited from MRIdian systems, which are installed in 57 hospitals worldwide.